You are in the accessibility menu

Please use this identifier to cite or link to this item: http://acervodigital.unesp.br/handle/11449/133761
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBosquesi, Priscila Longhin-
dc.contributor.authorMelo, Tais Regina Ferreira-
dc.contributor.authorVizioli, Ednir de Oliveira-
dc.contributor.authorSantos, Jean Leandro dos-
dc.contributor.authorChung, Man Chin-
dc.date.accessioned2016-01-28T16:56:31Z-
dc.date.accessioned2016-10-25T21:28:49Z-
dc.date.available2016-01-28T16:56:31Z-
dc.date.available2016-10-25T21:28:49Z-
dc.date.issued2011-
dc.identifierhttp://dx.doi.org/10.3390/ph4111450-
dc.identifier.citationPharmaceuticals, v. 4, p. 1450-1474, 2011.-
dc.identifier.issn1424-8247-
dc.identifier.urihttp://hdl.handle.net/11449/133761-
dc.identifier.urihttp://acervodigital.unesp.br/handle/11449/133761-
dc.description.abstractThe design of new drugs with better physiochemical properties, adequateabsorption, distribution, metabolism, and excretion, effective pharmacologic potency andlacking toxicity remains is a challenge. Inflammation is the initial trigger of severaldifferent diseases, such as Alzheimer s disease, asthma, atherosclerosis, colitis, rheumatoidarthritis, depression, cancer; and disorders such as obesity and sexual dysfunction.Although inflammation is not the direct cause of these disorders, inflammatory processesoften increase related pain and suffering. New anti-inflammatory drugs developed usingmolecular hybridization techniques to obtain multiple-ligand drugs can act at one or multipletargets, allowing for synergic action and minimizing toxicity. This work is a review of newanti-inflammatory drugs developed using the molecular modification approach.en
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)-
dc.description.sponsorshipConselho Nacional de Pesquisa (CNPq)-
dc.format.extent1450-1474-
dc.language.isoeng-
dc.sourceCurrículo Lattes-
dc.subjectAnti-inflammatoryen
dc.subjectHybridizationen
dc.subjectMultiple-ligandsen
dc.subjectMutual prodrugen
dc.titleAnti-inflammatory drug design by molecular hybridization approachen
dc.typeoutro-
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)-
dc.description.affiliationUniversidade Estadual Paulista Júlio de Mesquita Filho (UNESP), Faculdade de Ciências Farmacêuticas de Araraquara (FCFAR), Departamento de Fármacos e Medicamentos, Rodovia Araraquara-Jaú, km 1, Campus Ville, CEP 14801902, Araraquara, SP, Brasil-
dc.description.affiliationUnespUniversidade Estadual Paulista Júlio de Mesquita Filho (UNESP), Faculdade de Ciências Farmacêuticas de Araraquara (FCFAR), Departamento de Fármacos e Medicamentos, Rodovia Araraquara-Jaú, km 1, Campus Ville, CEP 14801902, Araraquara, SP, Brasil-
dc.description.sponsorshipIdFAPESP: 2010/12495-6-
dc.description.sponsorshipIdFAPESP: 2010/50330-9-
dc.description.sponsorshipIdCNPq: 308157/2010-9-
dc.identifier.doi10.3390/ph4111450-
dc.rights.accessRightsAcesso aberto-
dc.identifier.fileISSN1424-8247-2011-04-1450-1474.pdf-
dc.relation.ispartofPharmaceuticals-
dc.identifier.lattes5737933639516944-
dc.identifier.lattes3204277043366119-
dc.identifier.lattes5435899068903487-
dc.identifier.lattes4083068210623663-
Appears in Collections:Artigos, TCCs, Teses e Dissertações da Unesp

There are no files associated with this item.
 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.